Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen M. DeMoss who wrote (658)	12/25/1997 12:39:00 PM
From: Premier	Read Replies (2) \| Respond to of 2068

Steve: IMHO. Premium increase is very likely. This action should cause minimal defections because their rates are on the low side and competition is raising the rates anyway. A company sells new equity if it feels its stock is overvalued and it sells debt if it feels its common stock is undervalued. Wiggin's action will send a message to the market. A sale of minority interest will bring new capital to the company but it will be dilutive. The regulators have asked the company to appoint two outside board members and strengthen the management. OXHP's fraud unit has five employees, an increase in satffing in this area would achieve significant saving to the company. Even though stock price may continue southward over the short term, IMHO, the talks of OXHP's death are premature. Premier